<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687021</url>
  </required_header>
  <id_info>
    <org_study_id>yuqi03029</org_study_id>
    <nct_id>NCT03687021</nct_id>
  </id_info>
  <brief_title>Clinical Study on Endometrial Receptivity</brief_title>
  <official_title>Clinical Study on the Impact of Route of Administration of Progesterone and Endometriosis on Endometrial Receptivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      to explore the differential expression of miRNA in the implantation window of patients with
      endometriosis and the time of progesterone and route of administration on planting window
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2018</start_date>
  <completion_date type="Anticipated">November 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial receptivity measured by pathology</measure>
    <time_frame>3 months</time_frame>
    <description>35 samples will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrial receptivity measured by immunohisochemistry</measure>
    <time_frame>3 months</time_frame>
    <description>35 samples will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial receptivity measured by Ribose Nucleic Acid （RNA）</measure>
    <time_frame>3 months</time_frame>
    <description>35 samples will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial receptivity measured by scanning electron microscope</measure>
    <time_frame>3 months</time_frame>
    <description>35 samples will be measured</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Endometrial Receptivity;RNA; Progesterone</condition>
  <arm_group>
    <arm_group_label>endometriosis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>tissue biopsy from patients (n=10) with endometriosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without endometriosis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>tissue biopsy from patients (n=10) without endometriosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular progestin(20mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaginal progestin (90mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral progestin(40mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Different routes of administration of progesterone; Whether there is endometriosis</description>
    <arm_group_label>Intramuscular progesterone</arm_group_label>
    <arm_group_label>oral progesterone</arm_group_label>
    <arm_group_label>vaginal progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The endometriosis group treatment group: Previous laparoscopy or laparotomy confirmed
             endometriosis;Regular menstruation, no rule vaginal bleeding;Ovarian reserve function
             is normal.

             control group: Laparoscopic bilateral salpingectomy was performed due to ectopic
             pregnancy, benign ovarian changes and other reasons, with the exception of
             endometriosis during the operation.Regular menstruation, no rule vaginal
             bleeding;Ovarian reserve function is normal

          2. progesterone group Women with hypothalamic amenorrhea or premature ovarian
             failure;Ages 18-40

        Exclusion Criteria:

        Patients with medical complications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qi Yu, profssor</last_name>
      <phone>18612671865</phone>
      <email>yuqi2008001@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Xi Wang</last_name>
      <phone>13121133350</phone>
      <email>wangxi2008001@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial receptivity</keyword>
  <keyword>RNA</keyword>
  <keyword>progesterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

